Back to top
more

Hologic (HOLX)

(Delayed Data from NSDQ)

$79.29 USD

79.29
1,037,884

-1.20 (-1.49%)

Updated Nov 7, 2024 03:59 PM ET

After-Market: $79.32 +0.03 (0.04%) 5:54 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (63 out of 251)

Industry: Medical - Instruments

Zacks News

Hologic (HOLX) Q4 Earnings & Revenues Top, Margins Down

Solid double-digit growth at Hologic's (HOLX) molecular diagnostics and international business drives the top line in Q4.

    Can Molecular Diagnostics Drive Hologic's (HOLX) Q4 Earnings?

    Hologic (HOLX) is expected to deliver solid results in Q4 on the back of the increasing market share and utilization of fully-automated Panther system.

      3 Plastic & Reconstructive Surgery Stocks Looking Good

      Consider these three stocks for raking in grand returns from the fast-growing plastic and reconstructive surgery market.

        Hologic's Panther Fusion Flu A/B/RSV Assay Gets FDA Approval

        Hologic's (HOLX) receipt of FDA approval for Panther Fusion Flu A/B/RSV assay running on the new Panther Fusion system is likely to boost its Diagnostic segment.

          Hologic (HOLX) Down 11.1% Since Earnings Report: Can It Rebound?

          Hologic (HOLX) reported earnings more than a month ago. What's next for the stock? We take a look at earnings estimates for some clues.

            Hologic (HOLX) Launches Brevera, Progresses in Breast Health

            Hologic's (HOLX) Brevera real-time breast biopsy and verification system holds great potential to enhance workflow and patient experience.

              Hologic (HOLX) Beats on 3Q Earnings, Cuts Revenue Guidance

              Hologic's (HOLX) revenue growth in molecular diagnostics and GYN Surgical offset by poor blood screening and Breast Imaging show.

                MedTech Stock Earnings Slated for Aug 2: CAH, HOLX & More

                Despite solid strategic initiatives, the ongoing political conundrum at the Capitol Hill is likely to affect earnings results of these four major Medical Technology bigwigs.

                  What's in the Offing for Hologic (HOLX) in Q3 Earnings?

                  Hologic's (HOLX) gain through product launch and Cynosure integration may get hampered by a dull Cytology performance.

                    Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical

                    Zacks Industry Outlook Highlights: Teleflex, Medtronic, Johnson & Johnson, Hologic and Wright Medical

                      Hologic (HOLX) Product Pipeline Strong, Competition Rife

                      On Jun 27, we issued an updated research report on Hologic, Inc. (HOLX), headquartered in Bedford, MA.

                        Hologic (HOLX) Gets FDA Clearance for Aptima HSV 1 & 2 Test

                        Hologic, Inc. (HOLX) recently received FDA approval for the commercial launch of the Aptima Herpes Simplex Virus (HSV) 1 & 2 molecular assay on the fully automated Panther system.

                          Hologic Receives Extended FDA Clearance for SculpSure in US

                          Hologic, Inc. (HOLX) declared that the company's subsidiary Cynosure has received FDA's expanded clearance for SculpSure.

                            Hologic (HOLX) Up 3.5% Since Earnings Report: Can It Continue?

                            Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                              Hologic Wins FDA Approval for Genius 3D Mammography Exam

                              Hologic, Inc. (HOLX) continues to expand its Breast and Skeletal Health business through innovation and product development.

                                Envision (EVHC) Acquires Gwinnett Emergency Specialists

                                Envision Healthcare Corporation (EVHC) announced the acquisition of Gwinnett Emergency Specialists, P.C.

                                  Halyard Health (HYH) Expands CORGRIP System Product Line

                                  Halyard Health (HYH), a leading medical technology company, recently announced the expansion of its CORGRIP Nasogastric/Nasointestinal Tube Retention System product line.

                                    Hologic (HOLX) Poised on Balanced Growth Amid Currency Woes

                                    On May 23, we issued an updated research report on Bedford, MA-based Hologic Inc. (HOLX).

                                      Integra Lifesciences Hits 52-Week High on Product Launches

                                      Share price of Plainsboro NJ-based Integra Lifesciences Corporation (IART) reached a new 52-week high of $47.50 on May 19, finally closing a tad lower at $47.39.

                                        Quest Diagnostics Poised on Solid Q1 Results Despite Woes

                                        On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.

                                          Intuitive Surgical at 52-Week High: What's Driving the Stock?

                                          Share price of Sunnyvale, CA-based Intuitive Surgical Inc (ISRG) scaled a new 52-week high of $874.54 on May 19, eventually closing a bit lower at $870.33.

                                            Quality Systems (QSII) Beats Q4 Earnings, Issues FY18 View

                                            Irvine, CA-based Quality Systems Inc. (QSII) reported fourth-quarter fiscal 2017 adjusted earnings of 18 cents per share, exceeding the Zacks Consensus Estimate by a penny. Earnings remained flat on a year-over-year basis.

                                              Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint

                                              Medtronic plc (MDT) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent.

                                                McKesson (MCK) Beats Earnings Estimate in Q4, Revenues Miss

                                                McKesson Corporation (MCK) reported fourth-quarter fiscal 2017 earnings of $3.39 per share, beating the Zacks Consensus Estimate of $3.04.

                                                  Halyard Health-Sustainable Solutions Ink License Agreement

                                                  Halyard Health (HYH) announced a new license and supply agreement with Sustainable Solutions. The license agreement is aimed at converting recycled HALYARD Wrap into an environment friendly product for healthcare facilities.